Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 3/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11287487 | 0.85 | GRIK1 (0.47) | SLC1A2SLC1A1GRIK1GRIK2SLC1A3 | |
| SCHEMBL1372792 | 0.76 | SLC1A2 (0.47) | SLC1A2SLC1A1GRIK1GRIK2SLC1A3 | |
| SCHEMBL19411253 | 0.75 | GRIK1 (0.35) | SLC1A2SLC1A1GRIK1GRIK2SLC1A3 | |
| SCHEMBL28504041 | 0.73 | CA2 (0.38) | SLC1A2SLC1A1SLC1A3CHRM1AKR1A1 | |
| SCHEMBL8345116 | 0.68 | MAPT (0.30) | — | |
| SCHEMBL15018035 | 0.68 | GPR84 (0.40) | — | |
| SCHEMBL9482413 | 0.67 | SLC1A2 (0.39) | SLC1A2SLC1A1GRIK1GRIK2SLC1A3 | |
| SCHEMBL9480412 | 0.67 | SLC1A2 (0.39) | SLC1A2SLC1A1GRIK1GRIK2SLC1A3 | |
| Propane SCHEMBL27465982 | 0.67 | — | — | |
| Isobutane SCHEMBL27468822 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10982007-B2 | Detection of a posttranslationally modified polypeptide by a bivalent binding agent | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200277406-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2020-09-03 | — | — | US | disclosed |
| US-10633460-B2 | Binding agent | ROCHE DIAGNOSTIC OPERATIONS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-2655413-B1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN LA ROCHE (CH) | 2019-01-16 | — | — | EP | disclosed |
| EP-2655414-B1 | BISPECIFIC BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2018-08-29 | — | — | EP | disclosed |
| EP-2659275-B1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| EP-2867255-B1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2659269-B1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-2659269-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | Roche Diagniostics GmbH (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289251-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| EP-2655414-A1 | BINDING AGENT | Roche Diagniostics GmbH (DE) | 2013-10-30 | — | — | EP | disclosed |
| EP-2655413-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085069-A2 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085064-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085113-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085111-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289251-A1 | BINDING AGENT | SSB, APBA1, SHBG | SLC1A2 2094/4885SLC1A1 2051/4885GRIK1 3828/4885 |
| US-10982007-B2 | Detection of a posttranslationally modified polypeptide by a bivalent binding agent | PTMS, CD2BP2, PSMA2 | SLC1A2 3232/4885SLC1A1 3772/4885GRIK1 3013/4885 |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | PTMS, CD2BP2, PSMA2 | SLC1A2 3232/4885SLC1A1 3772/4885GRIK1 3013/4885 |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | PTMS, DNPEP, CD2BP2 | SLC1A2 2071/4885SLC1A1 1831/4885GRIK1 2524/4885 |
| US-10633460-B2 | Binding agent | SSB, APBA1, SHBG | SLC1A2 2105/4885SLC1A1 2044/4885GRIK1 3840/4885 |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | PA2G4, BRDT, CD2BP2 | SLC1A2 4313/4885SLC1A1 4669/4885GRIK1 2852/4885 |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | PA2G4, BRDT, CD2BP2 | SLC1A2 4313/4885SLC1A1 4669/4885GRIK1 2852/4885 |
| US-20200277406-A1 | BINDING AGENT | SSB, APBA1, SHBG | SLC1A2 2105/4885SLC1A1 2044/4885GRIK1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.